UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004175
Receipt number R000004929
Scientific Title Study of oral neurokinin-1 antagonist, aprepitant for prevention of nausea and emesis in patients receiving chemotherapy including cisplatin for gastric cancer.
Date of disclosure of the study information 2010/10/01
Last modified on 2013/01/28 22:07:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study of oral neurokinin-1 antagonist, aprepitant for prevention of nausea and emesis in patients receiving chemotherapy including cisplatin for gastric cancer.

Acronym

Effect of aprepitant in patient recieving chemotherapy including cisplatin for gastric cancer.

Scientific Title

Study of oral neurokinin-1 antagonist, aprepitant for prevention of nausea and emesis in patients receiving chemotherapy including cisplatin for gastric cancer.

Scientific Title:Acronym

Effect of aprepitant in patient recieving chemotherapy including cisplatin for gastric cancer.

Region

Japan


Condition

Condition

gastric cancer

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy and safety of aprepitant for prevention of nausea and emesis in patients receiving chemotherapy involving cisplatin for gastric cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Ratio of complete response (defined as no emesis and no rescue treatment). [Time Frame: overall; 0-120hr(during and post chemotherapy), acute phase;0-24hr, delayed phase 24-120hr] .

Key secondary outcomes

1) ratio of patient without emesis.
2) ratio of patient without resque treatment.
3) ratio of patient without neusea.
4) time to first emesis.
5) evaluation of volume of meal intake.
6) evaluation of QOL with Functional Living index-Emesis (FLIE) scale.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

We use three antiemetic drugs (aprepitant/granisetron/dexamethasone) for this trial.
aprepitant: oral administration, 125mg; 1 hour before chemotherapy on day1, 80mg; after breakfast on day2-3.
granisetron: 0.04mg/kg; intravenous administration, before chemotherapy on day1.
dexamethasone: 9.9mg; intravenous administration, before chemotherapy on day1, 8mg; oral administration, day 2-3.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) chemotherapy-naive ( including cisplatin, dose intensity; more than 10mg/week) patients with gastric cancer.
2) aged 20 years or more.
3) patents had undergone treatment with high emetic risk and moderate emetic risk chemotherapy prior to this study
4) written informed consent from the patients.

Key exclusion criteria

1) patients with serious hepatic insufficiency or renal failure.
2) patients with emesis within 24 hours before first administrating of cisplatin.
3) patients who were administered antiemetic drugs within 48 hours before first administrating of cisplatin.
4) patients with emetic factor except for chmotherapy
5) patient who was intended radiation therapy
6) patients judged inappropriate for this study by physicians.
7) patients who received Pimozide.


Target sample size

55


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Sachio Fushida

Organization

Kanazawa University

Division name

Division of gastroenterologic surgery

Zip code


Address

13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name

Organization

Kanazawa University

Division name

Division of gastroenterologic surgery

Zip code


Address


TEL


Homepage URL


Email



Sponsor or person

Institute

Division of gastroenterologic surgery, Kanazawa University

Institute

Department

Personal name



Funding Source

Organization

Division of gastroenterologic surgery, Kanazawa University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

Addition of aprepitant to standard antiemetic
therapy was effective in gastric cancer patients
undergoing treatment with cisplatin and S-1.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 10 Month 01 Day

Date of IRB


Anticipated trial start date

2010 Year 10 Month 01 Day

Last follow-up date

2012 Year 05 Month 01 Day

Date of closure to data entry

2012 Year 05 Month 01 Day

Date trial data considered complete

2012 Year 06 Month 01 Day

Date analysis concluded

2012 Year 08 Month 01 Day


Other

Other related information



Management information

Registered date

2010 Year 09 Month 08 Day

Last modified on

2013 Year 01 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004929


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name